异基因造血干细胞移植危重受者的结局研究
该多中心回顾性队列纳入2015至2020年法国14个ICU收治的1164例异基因造血干细胞移植(Allo-HSCT)患者,主要终点为90天死亡率。ICU死亡率为26%,90天、1年和3年死亡率分别为48%、63%和70%;年龄>56岁、移植后30-90天入ICU、激素难治性急性GVHD、需血管活性药和机械通气与90天死亡率独立相关。
要点
- 多数危重Allo-HSCT受者存活出院,总体90天生存率达51.8%。
- 需机械通气者死亡率随危险因素数量增加而升高,从39%至100%。
- 存在两个及以上死亡危险因素时需仔细评估治疗目标。
核心结论
- 多数危重Allo-HSCT受者存活ICU住院,包括需要机械通气者,总体90天生存率达51.8%。
主要发现
- 入ICU时66%(765例)存在多器官功能障碍,40%(461例)有急性呼吸衰竭,SOFA评分中位数6(IQR 4-8)。
- 38%(438例)需有创机械通气,19%(221例)需肾脏替代治疗,41%(468例)需血管活性药。
- ICU死亡率为26%(302例死亡),90天、1年和3年死亡率分别为48%、63%和70%。
- 多因素分析显示年龄>56岁(OR 2.0,95%CI 1.53-2.60,P<0.001)、移植至入ICU时间30-90天(OR 1.68,95%CI 1.17-2.40,P=0.005)、激素难治性急性GVHD(OR 1.63,95%CI 1.38-1.93,P<0.001)、需血管活性药(OR 1.9,95%CI 1.42-2.55,P<0.001)和机械通气(OR 3.1,95%CI 2.29-4.18,P<0.001)与90天死亡率独立相关。
- 需机械通气患者中,无其他死亡危险因素者死亡率为39%,有四个相关危险因素者死亡率为100%。
临床怎么用
- 危重Allo-HSCT受者不应默认排除ICU管理,多数患者可存活ICU住院。
- 对存在两个及以上死亡危险因素的患者,需仔细评估治疗目标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Allogeneic hematopoietic stem-cell transplantation (Allo-HSCT) recipients are still believed to be poor candidates for ICU management. Methods: We investigated outcomes and determinants of mortality in a large multicenter retrospective cohort of Allo-HSCT patients admitted between January 1, 2015, and December 31, 2020, to 14 French ICUs. The primary endpoint was 90-day mortality. Measurements and Main Results: In total, 1,164 patients were admitted throughout the study period. At the time of ICU admission, 765 (66%) patients presented with multiple organ dysfunction, including acute respiratory failure in 40% (n = 461). The median sepsis-related organ failure assessment score was 6 (interquartile range, 4-8). Invasive mechanical ventilation, renal replacement therapy, and vasopressors were required in 438 (38%), 221 (19%), and 468 (41%) patients, respectively. ICU mortality was 26% (302 deaths). Ninety-day, 1-year, and 3-year mortality rates were 48%, 63%, and 70%, respectively. By multivariable analysis, age > 56 years (odds ratio [OR], 2.0 [95% confidence interval (CI), 1.53-2.60]; P < 0.001), time from Allo-HSCT to ICU admission between 30 and 90 days (OR, 1.68 [95% CI, 1.17-2.40]; P = 0.005), corticosteroid-refractory acute graft-versus-host disease (OR, 1.63 [95% CI, 1.38-1.93]; P < 0.001), need for vasopressors (OR, 1.9 [95% CI, 1.42-2.55]; P < 0.001), and mechanical ventilation (OR, 3.1 [95% CI, 2.29-4.18]; P < 0.001) were independently associated with 90-day mortality. In patients requiring mechanical ventilation, mortality rates ranged from 39% (no other risk factors for mortality) to 100% (four associated risk factors for mortality). Conclusions: Most critically ill Allo-HSCT recipients survive their ICU stays, including those requiring mechanical ventilation, with an overall 90-day survival rate reaching 51.8%. A careful assessment of goals of care is required in patients with two or more risk factors for mortality.
引用
- Lafarge A, Dupont T, Canet E, et al. Outcomes in Critically Ill Allogeneic Hematopoietic Stem-Cell Transplantation Recipients. Am J Respir Crit Care Med. 2024. PMID: 39018219. doi:10.1164/rccm.202401-0135OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。